JAMA Network
About The Study: The results of this study suggest that young breast cancer survivors without a germline pathogenic variant have a low risk of developing a second primary breast cancer in the first 10 years after diagnosis. Findings from germline genetic testing may inform treatment decision-making and follow-up care considerations in this population.
Authors: Kristen D. Brantley, Ph.D., M.P.H., of the Harvard T. H. Chan School of Public Health in Boston, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamaoncol.2024.0286)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
